02 Jul 2020, Ghent, Belgium,
myNEO announces that promising Covid-19 peptides have been identified which will undergo further preclinical testing. By making smart use of existing cancer treatment technology, the Covid-19 vaccine aims to provide long-term protection to more than 80% of the global population. The vaccine will fight all current Covid-19 forms and other viruses from the corona group such as SARS and MERS.
Now myNEO has found these promising Covid-19 peptides, the company starts pre-clinical trials in collaboration with a European biotech company with a cancer vaccine technology. The goal is to test the vaccine in early 2021 on humans.
For more information, read the recent press releases in Dutch, French or English or watch the interview by Kanaal Z in Dutch or French.